X

Trial Profile

A multicenter, open-label trial of low dose naltrexone for prevention of cervical cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Naltrexone (Primary)
Indications Cervical cancer
Focus Adverse reactions

Most Recent Events

31 May 2017 According to an Immune Therapeutics media release, The company is ready to submit a New Drug Application (NDA) to the Directorate of Pharmacy and Medicines, the application will include results of four phase II clinical trials and one bridging trial clinical trial.
16 Sep 2016 New trial record
23 Aug 2016 According to an Immune Therapeutics media release, Dr, Frank Taulo from the OBGYN Department of Queen Elizabeth Central Hospital in Blantyre is the Principle Investigator of thsi trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com